Mersana Therapeutics (NASDAQ:MRSN) had its target price boosted by Wedbush from $15.00 to $16.00 in a research note issued on Tuesday. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target would indicate a potential upside of 29.55% from the stock’s current price.

MRSN has been the topic of a number of other research reports. HC Wainwright set a $16.00 price target on shares of Mersana Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 16th. Robert W. Baird set a $20.00 price target on shares of Mersana Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research lowered shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. ValuEngine upgraded shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 29th. Finally, Leerink Swann lowered shares of Mersana Therapeutics from an “outperform” rating to a “market perform” rating and set a $61.00 price target on the stock. in a research note on Thursday, July 19th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Mersana Therapeutics presently has an average rating of “Buy” and an average price target of $26.83.

Mersana Therapeutics stock traded up $0.18 during mid-day trading on Tuesday, reaching $12.35. 496 shares of the company traded hands, compared to its average volume of 147,649. Mersana Therapeutics has a fifty-two week low of $8.76 and a fifty-two week high of $23.96. The firm has a market capitalization of $332.95 million, a price-to-earnings ratio of -3.78 and a beta of -1.89.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings results on Wednesday, August 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.04. Mersana Therapeutics had a negative net margin of 276.81% and a negative return on equity of 72.63%. The business had revenue of $4.19 million for the quarter, compared to analyst estimates of $3.74 million. equities research analysts anticipate that Mersana Therapeutics will post -2.32 EPS for the current fiscal year.

In other news, insider Timothy B. Lowinger sold 3,500 shares of the stock in a transaction on Monday, August 27th. The shares were sold at an average price of $13.15, for a total value of $46,025.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 39.70% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the company. Northern Trust Corp increased its stake in shares of Mersana Therapeutics by 111.0% in the first quarter. Northern Trust Corp now owns 111,669 shares of the company’s stock worth $1,761,000 after acquiring an additional 58,743 shares during the period. Spark Investment Management LLC increased its stake in shares of Mersana Therapeutics by 91.8% in the first quarter. Spark Investment Management LLC now owns 24,929 shares of the company’s stock worth $393,000 after acquiring an additional 11,929 shares during the period. California State Teachers Retirement System increased its stake in shares of Mersana Therapeutics by 107.7% in the first quarter. California State Teachers Retirement System now owns 17,035 shares of the company’s stock worth $269,000 after acquiring an additional 8,835 shares during the period. American International Group Inc. grew its position in Mersana Therapeutics by 110.1% during the first quarter. American International Group Inc. now owns 7,151 shares of the company’s stock valued at $113,000 after buying an additional 3,747 shares during the period. Finally, Russell Investments Group Ltd. acquired a new stake in Mersana Therapeutics during the first quarter valued at $676,000. Hedge funds and other institutional investors own 82.61% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.

See Also: How are Outstanding Shares Different from Authorized Shares?

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.